Novus Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 24-10-2024
- Revenue 12.71%
(FY 2023)
- Profit 34.81%
(FY 2023)
- Ebitda 45.17%
(FY 2023)
- Net Worth 14.85%
(FY 2023)
- Total Assets 49.21%
(FY 2023)
About Novus Remedies
The Company is engaged in the Environment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Ashish Saraf, Omprakash Saraf, and Vijay Shinde serve as directors at the Company.
- CIN/LLPIN
U40100MH2008PTC185174
- Company No.
185174
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Novus Remedies Private Limited offer?
Novus Remedies Private Limited offers a wide range of products and services, including Solar & Renewable Energy Products, Solar Power Plants.
Who are the key members and board of directors at Novus Remedies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Omprakash Saraf  | Director | 10-Dec-2022 | Current |
| Ashish Saraf | Director | 01-Mar-2022 | Current |
| Vijay Shinde | Additional Director | 02-Jan-2024 | Current |
Financial Performance of Novus Remedies.
Novus Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.71% increase. The company also saw a substantial improvement in profitability, with a 34.81% increase in profit. The company's net worth Soared by an impressive increase of 14.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novus Remedies?
In 2023, Novus Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Sep 2023 | ₹4.00 M | Open |
How Many Employees Work at Novus Remedies?
Novus Remedies has a workforce of 3 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novus Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novus Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
